Clonox Mechanism of Action

enoxaparin sodium


Mega Lifesciences


Full Prescribing Info
Pharmacology: Pharmacodynamics: Enoxaparin is a low molecular weight heparin with high anti Xa activity (100 I.U./mg) and with a low anti II or anti thrombotic activity (28 IU/mg). At doses required for various indications, enoxaparin does not increase bleeding time. At preventive doses, Enoxaparin causes no notable modification of APTT. It neither influences platelet aggregation nor binding of fibrinogen to platelets.
Mechanism of Action: Enoxaparin is a low molecular weight heparin which has antithrombotic properties.
Pharmacokinetics: The pharmacokinetic parameters have been studied in terms of the time course of plasma anti-Xa activity.
Bioavailability: After subcutaneous injection, enoxaparin is rapidly and completely absorbed. The bioavailability of enoxaparin is close to 95%.
Distribution: After subcutaneous injection, the maximum plasma activity is obtained 3 hours after the administration.
The anti-Xa activity is located in the vascular space.
Biotransformation: Enoxaparin is primarily metabolized in the liver.
Elimination: The elimination half-life of anti-Xa activity is approximately 4.4 hours after administration of 40 mg of enoxaparin and 4 hours for an administration of 60 mg or 80 mg of enoxaparin.
Excretion: Enoxaparin is eliminated in the urine. In the elderly, the elimination is slightly decreased.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in